LOS ANGELES--(BUSINESS WIRE)--Glancy Binkow & Goldberg LLP announces that it is investigating potential claims on behalf of shareholders of BioScrip, Inc. (“BioScrip” or the “Company”) (NASDAQ:BIOS) concerning possible breaches of fiduciary duties by the Company or its fiduciaries. The investigation is focused on certain statements issued by the Company concerning BioScrip’s business and operations.
Please contact us at 212-682-5340, Toll-Free at 888-773-9224, or at shareholders@glancylaw.com to discuss this matter. If you inquire by email please include your mailing address, telephone number and number of shares purchased.
BioScrip provides home infusion, other home care services, and pharmacy benefit management services in the United States. On September 23, 2013, the Company disclosed that the United States Attorney’s Office for the Southern District of New York and the New York State Attorney General’s Medicaid Fraud Control Unit have undertaken an investigation regarding the distribution of the Novartis Pharmaceuticals Corporation product Exjade(R) by the Company’s legacy specialty pharmacy division. The Company further disclosed that it has provided documents and information to the government regarding the distribution of Exjade, pursuant to a civil investigative demand and a subpoena. Following this news, the price of BioScrip shares declined more than 18%, to a closing price of $8.47 per share on September 24, 2013.
If you purchased BioScrip shares and still hold those shares, if you have information or would like to learn more about these claims, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Michael Goldberg, Esquire, of Glancy Binkow & Goldberg LLP, 1925 Century Park East, Suite 2100, Los Angeles, California 90067, Toll-Free at 888-773-9224, or contact Gregory Linkh, Esquire, of Glancy Binkow & Goldberg LLP at 122 E. 42nd Street, Suite 2920, New York, New York 10168, at 212-682-5340, by e-mail to shareholders@glancylaw.com, or visit our website at http://www.glancylaw.com. If you inquire by email, please include your mailing address, telephone number and number of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
